Sign In
Buy SNOA
$1.14
-0.0200 (-1.72%)
At Close: Jun 23, 2026
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA
04:47pm, Wednesday, 16'th Dec 2020
New York, New York--(Newsfile Corp. - December 16, 2020) - Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. ("Sonoma" or the "Company") (NASDAQ: SNOA). Such
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA
08:08pm, Saturday, 12'th Dec 2020
NEW YORK, Dec. 12, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. (“Sonoma” or the “Company”) (NASDAQ: SNOA). Such in
Sonoma Pharmaceuticals News Alert: Why SNOA Stock Is Rocketing Higher Today
10:37am, Friday, 11'th Dec 2020
Sonoma Pharmaceuticals (SNOA) is in the news Friday after announcing a deal with Crown Laboratories that has SNOA stock on the rise. The post Sonoma Pharmaceuticals News Alert: Why SNOA Stock Is Rocke
ROSEN, GLOBAL INVESTOR COUNSEL, Continues Its Investigation of Securities Claims Against Sonoma Pharmaceuticals, Inc. - SNOA
03:47pm, Tuesday, 08'th Dec 2020
New York, New York--(Newsfile Corp. - December 8, 2020) - Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Son
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA
08:13pm, Monday, 07'th Dec 2020
NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. (“Sonoma” or the “Company”) (NASDAQ: SNOA). Such in
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sonoma Pharmaceuticals, Inc. – SNOA
08:46pm, Monday, 30'th Nov 2020
NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. (“Sonoma” or the “Company”) (NASDAQ: SNOA). Such invest
LOS ANGELES--(BUSINESS WIRE)---- $SNOA #SNOA--ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA
11:20pm, Wednesday, 25'th Nov 2020
NEW YORK, Nov. 25, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. ("Sonoma" or the "Company") (NASDAQ: SNOA). Such investors are advi
Sonoma Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm
08:26pm, Wednesday, 25'th Nov 2020
Investors can contact the law firm at no cost to learn more about recovering their losses Investors can contact the law firm at no cost to learn more about recovering their losses
Los Angeles, California--(Newsfile Corp. - November 25, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors o
ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. - SNOA
08:47pm, Tuesday, 24'th Nov 2020
NEW YORK, Nov. 24, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc
Sonoma Pharmaceuticals Reports Second Quarter FY 2021 Financial Results
04:21pm, Friday, 20'th Nov 2020
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of appli
